Brazil Adult Vaccines Market Overview, 2031

The adult vaccines market in Brazil is playing an increasingly important role in public health as the country seeks to extend immunization beyond childhood and cover a broader adult population for diseases such as influenza, pneumococcal disease, hepatitis, yellow fever, and other vaccine preventable illnesses. With a mature public immunization infrastructure under the Sistema Único de Saúde (SUS), Brazil offers free-of-cost vaccines to adults, including older adults and high risk groups, supporting national immunization schedules and preventive health strategies. The growth of the adult vaccine market is bolstered by rising awareness of chronic disease risks, increasing life expectancy, and efforts to reduce burden on hospitals by preventing infectious disease outbreaks among working age and elderly populations. Local vaccine manufacturing capacity supported by national production institutions contributes to reliable supply and supports both routine immunizations and targeted adult vaccine campaigns. Despite challenges like vaccine hesitancy, logistical constraints, and disparities in access in remote or underserved regions, adult immunization remains a priority under Brazil’s public health policies. The expanding range of adult vaccines, combined with public funding, evolving disease burden, and heightened demand for preventive care, establishes the adult vaccines market as a vital and growing component of Brazil’s healthcare ecosystem.

The adult vaccines market in Brazil is shaped significantly by the country’s established immunization infrastructure, public health commitment, and growing demand from adult and elderly populations. Under national programs, Brazil provides a broad portfolio of vaccines free of cost to adults including seasonal influenza, pneumococcal, hepatitis, yellow fever, and other recommended vaccines ensuring widespread accessibility. The market benefits from domestic manufacturing capabilities, which reduce dependency on imports and support consistent supply of vaccines tailored to regional epidemiological needs. Demand is driven by increasing awareness of preventive healthcare, rising incidence of infectious diseases among adults, emphasis on protecting older and high risk populations, and public health campaigns aimed at improving vaccine uptake. However, vaccination coverage among adults remains challenged by variable uptake rates, occasional vaccine hesitancy, and logistical or socioeconomic barriers, especially in remote or underprivileged areas. Continued investments in vaccine distribution channels, outreach programs, and public education are gradually improving coverage. As Brazil boosts efforts to modernize its healthcare infrastructure and expand immunization access across urban and rural regions, the adult vaccines market is expected to expand further underpinned by government support, a robust manufacturing base, and increasing public demand for lifelong immunization to safeguard community health.

According to the research report, "Brazil Adult Vaccines Overview, 2031," published by Bonafide Research, the Brazil Adult Vaccines is anticipated to grow at more than 8.35% CAGR from 2026 to 2031.The adult vaccines market segment by type includes Monovalent Conjugate Vaccines and Multivalent Conjugate Vaccines, each playing a crucial role in preventing bacterial infections, especially among older adults and high-risk groups. Monovalent conjugate vaccines target a single bacterial strain or serotype by linking a purified polysaccharide antigen to a protein carrier, which enhances the immune response and provides long-lasting protection. These vaccines are widely used for specific infectious threats where a single serotype is responsible for most disease cases, helping generate strong immunological memory, better T-cell activation, and higher effectiveness among immunocompromised adults and the elderly. They are often recommended in targeted immunization strategies where precision protection is needed, such as certain meningococcal or pneumococcal risk categories. In contrast, Multivalent conjugate vaccines combine multiple serotypes into a single formulation, offering broader coverage against several bacterial strains simultaneously, making them especially valuable in countries with diverse circulating serotypes or high disease burden. These vaccines provide extensive protection, reduce healthcare visits, and support herd immunity by lowering community transmission. They are commonly used in large-scale adult immunization programs for diseases like pneumococcal infections, where Mult serotype protection is essential to prevent severe complications such as pneumonia, sepsis, and meningitis. The growing preference for multivalent options is driven by their convenience, comprehensive coverage, and ability to reduce the need for multiple immunization doses. Both monovalent and multivalent conjugate vaccines are supported by advancements in protein conjugation technology, strong clinical evidence, and rising public-health emphasis on preventing bacterial infections among adults, particularly those aged 50 and above.

The adult vaccines market segmented by disease includes a wide range of immunization products addressing critical viral and bacterial infections, with each category contributing uniquely to overall disease prevention among adults of different age groups. Varicella vaccines protect against chickenpox, which can cause severe complications in adults such as pneumonia and shingles later in life, making adult immunization essential for those without natural immunity. Human Papilloma Virus (HPV) vaccines are among the most impactful, as they protect against high-risk HPV strains linked to cervical, anal, oropharyngeal, and other cancers, with catch-up vaccination programs increasingly targeting both young adults and older adults at risk. Measles vaccines remain vital due to periodic outbreaks caused by declining immunity and incomplete vaccination histories, and adult boosters help maintain herd protection and reduce transmission in public environments. Similarly, Mumps and Rubella vaccines, often provided together as part of the MMR formulation, support adult immunity to prevent complications such as orchitis, encephalitis, and congenital rubella syndrome in pregnant women. One of the most significant segments is vaccines for Pneumococcal Disease, which pose serious risks for adults over 50, especially those with chronic illnesses; conjugate and polysaccharide formulations help protect against pneumonia, bloodstream infections, and meningitis. The Others category includes vaccines for diseases such as hepatitis A and B, influenza, meningococcal infections, tetanus, diphtheria, pertussis, and travel-related illnesses like typhoid or yellow fever, all of which are vital for different adult populations depending on lifestyle, occupation, medical conditions, and travel behaviour. Together, these disease-specific vaccines form the foundation of adult immunization strategies, reducing disease burden, improving public health resilience, and supporting long-term healthcare cost savings.

Considered in this report
• Historic year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031



Aspects covered in this report
• Adult Vaccines Market Outlook with its value and forecast along with its segments
• Brazil Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Types:
• Monovalent Conjugate Vaccines
• Multivalent Conjugate Vaccines

By Disease:
• Varicella
• Human Papilloma Virus
• Measles
• Mumps and Rubella
• Pneumococcal Disease
• Others